SG
SHPH icon

StoneX Group’s Shuttle Pharmaceuticals SHPH Stock Holding History

StoneX Group’s Portfolio SHPH Stock Details SHPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25
Closed -$22.8K – 706
2023
Q4 		$22.8K Buy
+25
New +$25.6K ﹤0.01% 559

Other funds holding SHPH

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

StoneX Group's SHPH Position: Q1 2024 in Review

StoneX Group sold out of Shuttle Pharmaceuticals (SHPH) in Q1 2024, closing a stake of 25 shares — an estimated $22.8K sold.

StoneX Group first reported a position in SHPH in Q4 2023 and held it in 1 quarter. The position peaked at $22.8K in Q4 2023. 4 funds tracked by Wall St. Rank hold SHPH as of Q1 2024.

  • StoneX Group reported no remaining Shuttle Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • StoneX Group sold 25 Shuttle Pharmaceuticals shares in Q1 2024, an estimated $22.8K.
  • StoneX Group first reported a position in Shuttle Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • StoneX Group's Shuttle Pharmaceuticals position peaked at $22.8K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q1 2024.

Based on StoneX Group's 13F filing for Q1 2024, filed 1 May 2024.